Diseases [C] » Hemic and Lymphatic Diseases [C15] » Hematologic Diseases » Bone Marrow Diseases » Myeloproliferative Disorders » Primary Myelofibrosis
Description
A de novo myeloproliferation arising from an abnormal stem cell. It is characterized by the replacement of bone marrow by fibrous tissue, a process that is mediated by CYTOKINES arising from the abnormal clone. MeSH
Hierarchy View
Approved Indicated Drugs (3)
Phase 3 Indicated Drugs (20)
Phase 2 Indicated Drugs (73)
Phase 1 Indicated Drugs (68)
Other Experimental Indicated Drugs (6)
Organization Involved with Phase 4 Indications (1)
Organization Involved with Phase 3 Indications (16)
Organization Involved with Phase 2 Indications (84)
Canadian Society of Hematology
Canadian Venous Thromboembolism Clinical Trials and Outcomes Research (CanVECTOR) Network
Case Western Reserve University
City of Hope National Medical Center
Developmental Therapeutics Consortium
Eastern Cooperative Oncology Group
French Acute Leukaemia and Blood Diseases West-East Group
Gruppo Italiano Trapianto di Midollo Osseo
HOVON - Dutch Haemato-Oncology Association
Icahn School of Medicine at Mount Sinai
Infinity Pharmaceuticals, Inc.
Katholieke Universiteit Leuven
Memorial Sloan-Kettering Cancer Center
National Heart, Lung, and Blood Institute (NHLBI)
National Institutes of Health (NIH)
North Central Cancer Treatment Group
Oregon Health and Science University
Pavlov First Saint Petersburg State Medical University
State University of New York, Buffalo
Organization Involved with Phase 1 Indications (31)
Organization Involved with Other Experimental Indications (2)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
